With only six months to go until a planned implementation date of Jan. 1, 2020, HHS last week pulled its controversial rule that would have eliminated pharmaceutical manufacturer rebates in Medicare and Medicaid, leaving Part D stakeholders to ponder the Trump administration’s next moves on lowering prescription drug pricing. Possibilities reportedly being considered at press time include capping price increases to an inflation factor and restructuring the catastrophic portion of the Part D benefit, which combined could be a one-two punch to manufacturers’ ability to raise prices, one industry expert suggests.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.